AMG National Trust Bank Reduces Position in Bristol Myers Squibb Company $BMY

AMG National Trust Bank trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 86.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,739 shares of the biopharmaceutical company’s stock after selling 103,958 shares during the period. AMG National Trust Bank’s holdings in Bristol Myers Squibb were worth $710,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Bristol Myers Squibb in the second quarter worth about $1,554,154,000. Charles Schwab Investment Management Inc. increased its holdings in Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after acquiring an additional 10,195,775 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Bristol Myers Squibb by 428.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after acquiring an additional 9,171,098 shares during the period. Man Group plc lifted its holdings in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after purchasing an additional 5,503,391 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Bristol Myers Squibb by 142.8% in the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock worth $390,541,000 after purchasing an additional 4,961,869 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

Bristol Myers Squibb Trading Up 0.6%

BMY stock opened at $60.66 on Monday. The firm has a fifty day moving average price of $56.22 and a 200 day moving average price of $50.03. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The firm has a market cap of $123.53 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the previous year, the business earned $1.67 earnings per share. The business’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Analysts Set New Price Targets

Several analysts have recently commented on BMY shares. Citigroup raised their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the stock from $46.00 to $65.00 in a research note on Wednesday, January 7th. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Morgan Stanley reaffirmed an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Scotiabank reissued a “sector perform” rating and set a $60.00 target price (up previously from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Nine equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $60.19.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.